Novartis’s heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction.

New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine.

Novartis’s big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain’s cost agency NICE, which said on Friday it believed the treatment was a cost-effective option.   Entresto has a list price of 1,194 pounds ($1,809) a year in Britain, or less than half the price of […]

Researchers at Brigham and Women’s Hospital have discovered even more promising data around a Novartis drug for heart failure, saying that the drug increased life expectancy by nearly two years. The research, published in the Dec. 3 issue of the New England Journal of Medicine, showed that patients that had reduced ejection fraction form — […]

The European Commission has approved Novartis’ Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday.   Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate […]

Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. Drug prices are set to be a major issue in the run-up to the U.S. presidential election next year, with Democratic candidate Hillary […]

Lowering blood pressure below a commonly used target dramatically reduced heart failure and risk of death in adults aged 50 and older in a large U.S. government-sponsored study, results that could lead to a change in treatment guidelines and medical practice.   The data presented on Monday had some potentially troubling side effects that researchers […]

Eli Lilly’s new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3-year trial of more than 7,000 patients caused a sensation in […]

An experimental heart failure drug being developed by Cytokinetics Inc and Amgen Inc demonstrated several beneficial cardiac function effects in a midstage clinical trial, according to data presented on Sunday. The trial of 448 patients with chronic heart failure already receiving optimal care tested a twice-a-day oral version of the drug, omecamtiv mecarbil, against a […]

The Novo Nordisk diabetes drug Victoza failed to improve clinical stability or delay death in patients suffering from advanced heart failure, researchers reported at a medical meeting on Sunday. The injectable drug, known chemically as liraglutide, was tested in 300 patients with and without type 2 diabetes who had advanced heart failure and a recent […]